Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration

Bisphosphonates (BPs) have recently been shown to have direct anti-tumor properties. Systemic treatment with BPs can have multiple adverse effects such as osteonecrosis of the jaw and BP induced bone fracturing and spine instability. While benefits of systemic BP treatments may outweigh risks, local...

Descripción completa

Detalles Bibliográficos
Autores principales: Nooh, Anas, Zhang, Yu Ling, Sato, Daisuke, Rosenzweig, Derek H., Tabariès, Sébastien, Siegel, Peter, Barralet, Jake E., Weber, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262502/
https://www.ncbi.nlm.nih.gov/pubmed/28138422
http://dx.doi.org/10.1016/j.jbo.2017.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5262502/
https://www.ncbi.nlm.nih.gov/pubmed/28138422
http://dx.doi.org/10.1016/j.jbo.2017.01.001

Ejemplares similares